Capacity-build delivers right dose for Laurus

Execution-led CDMO growth supports margins

- DEEPAK KORGAONKAR

Shares of contract development and manufacturing major Laurus Labs extended their upmove, gaining nearly 3 per cent to hit an intraday high of €1,103.35 on the BSE on ‘Thursday. Over the past two trading sessions, the pharmaceutical company’s stock has rallied 8 per cent.

Quoting close to its all-time high of %1,140.9, the stock ended the session at 1,092, up 1.52 per cent.

Over the past six months, Laurus shares have outperformed the market, rising 26 per cent compared with a 2 per cent gain in the Sensex. Over the past year, the stock has surged 101.5 per cent, against a 10.2 per cent rise in the benchmark index.

Laurus delivered a strong operational and financial performance in the third quarter (October-December/Q3) of 2025-26 (FY26). Revenue for Q3FY26 grew 26 per cent to ₹1,778 crore, while gross margins expanded sequentially to around 60 per cent. Operating profit margins, meanwhile, expanded to a little over 27 percent.

Management credited the performance to strong growth across its generics business, as well as clinical and commercial supplies under its contract development and manufacturing organisation (CDMO) programmes.